Whether 35 U.S.C. § 271(e)(4)(A) requires courts to issue injunctive orders that are broader in scope than the underlying infringement, thereby delaying FDA approval of generic drug applications for indications that have not been found to infringe any valid patent.

Whether 35 U.S.C. § 271(e)(4)(A) requires courts to issue overly broad injunctive orders that delay FDA approval of generic drug applications beyond the scope of actual patent infringement